Related Experiment Video
Updated: Mar 17, 2026

P300-Based Brain-Computer Interface Speller Performance Estimation with Classifier-Based Latency Estimation
Published on: September 8, 2023
Probability Based hERG Blocker Classifiers
Zhi Wang1, Hamse Y Mussa2, Robert Lowe2
1State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, 15 Bei San Huan East Road, P.O. Box 53, Beijing 100029, P. R. China telephone: +86-10-64421335, fax: +86-10-64416428.
Abstract:
The US Food and Drug Administration (FDA) require in vitro human ether-a-go-go related (hERG) ion channel affinity tests for all drug candidates prior to clinical trials. In this study, probabilistic-based methods were employed to develop prediction models on hERG inhibition prediction, which are different from traditional QSAR models that are mainly based on supervised 'hard point' (HP) classification approaches giving 'yes/no' answers. The obtained models can 'ascertain' whether or not a given set of compounds can block hERG ion channels. The results presented indicate that the proposed probabilistic-based method can be a valuable tool for ranking compounds with respect to their potential cardio-toxicity and will be promising for other toxic property predictions.
More Related Videos
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Related Concept Videos
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antihypertensive Drugs: Types of β-Blockers
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Hazard Ratio
For example, in a clinical trial...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers